ZSZhi-Hao Shi

Zhi-Hao Shi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhi-Hao Shi has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Fang Fang

    National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210023, China

    1 shared publication
  • Fang Fang

    National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, Jiangsu, China

    1 shared publication
  • Nian-Guang Li

    National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, Jiangsu 210023, China

    1 shared publication
  • Ting Gu

    National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210023, China

    1 shared publication
  • Wen-Yu Wu

    Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China

    1 shared publication
  • Ying Sun

    National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210023, China

    1 shared publication

Latest Publications

  • Open Access

    Synthesis and Bioactivity Characterization of Scutellarein Sulfonated Derivative

    by Ting Gu, Yue Zhong, Yu-Ting Lu, Ying Sun, Ze-Xi Dong, Wen-Yu Wu, Zhi-Hao Shi, Nian-Guang Li, Xin Xue, Fang Fang, et al.

    Scutellarin (1) has been widely used to treat acute cerebral infarction in clinic, but poor aqueous solubility decreases its bioavailability. Interestingly, scutellarin (1) could be metabolized into scutellarein (2) in vivo. In this study, a sulfonic group was introduced at position C-8 of scutellarein (2) to enhance the aqueous solubility of the obtained derivative (3). DPPH (1,1-diphenyl-2-picrylhydrazyl)-radical scavenging ability and antithrombic activity were also conducted to determine its bioactivity. The result showed that scutellarein derivate (3) could be a better agent for ischemic cerebrovascular disease treatment.